Minimed™ 780g system demonstrates superiority over multiple daily injections with cgm for type 1 diabetes management at one-year in adapt study

A second randomized controlled trial sponsored by jdrf also demonstrates superiority of automated insulin pump as first-in-line therapy for children with type 1 diabetes  dublin and berlin , feb. 24, 2023 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced one-year data from the adapt study (n=82), the first multi-national randomized controlled study comparing the performance of the minimed™ 780g advanced hybrid closed loop system1 (ahcl) against multiple daily injections (mdi) of insulin with an intermittently scanned cgm (iscgm). the study was done in adults (18 years of age and older) not meeting glycemic targets.
MDT Ratings Summary
MDT Quant Ranking